Thymosin Alpha-1 vs ARA-290
Both Thymosin Alpha-1 and ARA-290 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
Thymosin Alpha-1
Evidence AThymosin Alpha-1 (Tα1)
A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
View full Thymosin Alpha-1 profile →ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →Side-by-Side
| Attribute | Thymosin Alpha-1 | ARA-290 |
|---|---|---|
| Evidence Grade | A | B |
| FDA Status | Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations) | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy |
| Typical Dose | 1.6 mg twice weekly (subcutaneous) | Trial range: 1–4 mg subcutaneous daily |
| Clinics Indexed | 192 | 9 |
| Categories | immune, anti-inflammatory | anti-inflammatory, neuroprotection |
Key reported benefits — Thymosin Alpha-1
- ✓T-cell maturation
- ✓Antiviral immunity
- ✓Tumor immune support
- ✓Sepsis adjunct
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.